CereGate Company Research Report

Company Overview

• Name: CereGate

• Mission: To establish new ways of communication through Brain-Machine Interface technology, enabling patients with neurological disorders or sensory deficits to adapt and improve their condition under their own power. The guiding principles are increasing patient independence and improving quality of life.

• Founded By: No information is available.

• Key People: Dr. Bálint Várkuti, CEO

• Headquarters: No information is available.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: CereGate is known for developing a revolutionary neural interface system, aiming to merge clinical neuromodulation and brain-computer interfacing to create disruptive new therapy options.

Products

• Product Overview:

• CereGate’s technology is hardware-agnostic, aiming to develop therapeutic solutions that enable a broad range of applications from sensory substitution to improving gait.

• FOG-LIGHTS (Deep Brain Stimulation Freezing of Gait Therapy):

• Description: A software product targeting symptoms of Parkinson’s disease to enhance the functionality of implants, making them less glitchy and more personalized.

• Key Features: Improves gait and postural stability, enhances patient independence, and provides a personalized neural interface experience.

• Spinal Cord Stimulator (SCS) Computer-Brain Interface:

• Description: Repurposes existing spinal cord implants to serve as computer-brain interfaces capable of transmitting rhythmic cues and essential postural information.

• Key Features: High adaptability, enables a range of therapeutic applications, leverages existing SCS implant technology.

Recent Developments

• January 8, 2024: Scientific publication in "Brain Stimulation" journal demonstrated the repurposing of Spinal Cord Stimulator (SCS) implants into computer-brain interfaces, a collaboration with Dr. Loránd Erōss’s team in Budapest, Hungary. The innovation suggests broad clinical application potential.

• March 20, 2023: Dr. Bálint Várkuti, CEO, discussed future developments and accessibility for a wider range of applications in a podcast appearance, indicating scalability in CereGate’s roadmap.

• January 12, 2022: Secured additional funding from investors such as 468 Capital and re.Mind Capital, with a focus on expanding team and advancing clinical development efforts, particularly leveraging new applications for Spinal Cord Stimulation neuromodulation platforms.

Summary

CereGate continues to establish itself as a pioneer in the Computer-Brain Interface (CBI) field, driving forward advancements that may widely impact the treatment landscape for neurological disorders. Through strategic collaborations and securing influential capital investments, CereGate is on a promising path towards realizing its mission of enhancing patient autonomy and quality of life via groundbreaking neural interface solutions.